Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience

Ibrutinib is highly effective in patients with relapsed or refractory mantle cell lymphoma (MCL) in major clinical trials. Although there has been a dramatic improvement in survival outcomes in the salvage setting, nonresponders to ibrutinib have a bleak prognosis. Therefore, this retrospective stud...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Med
Autori principali: Jeon, Young‐Woo, Yoon, Seugyun, Min, Gi June, Park, Sung‐Soo, Park, Silvia, Yoon, Jae‐Ho, Lee, Sung‐Eun, Cho, Byung‐Sik, Eom, Ki‐Seong, Kim, Yoo‐Jin, Kim, Hee‐Je, Lee, Seok, Min, Chang‐Ki, Lee, Jong Wook, Cho, Seok‐Goo
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2019
Soggetti:
Clinical Cancer Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853811/
https://ncbi.nlm.nih.gov/pubmed/31560165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2565
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi